Printer Friendly

bluebird bio collaborates with Gritstone Oncology.

M2 EQUITYBITES-August 27, 2018-bluebird bio collaborates with Gritstone Oncology

(C)2018 M2 COMMUNICATIONS http://www.m2.com

It was reported on Friday that US-based bluebird bio has collaborated with US-based Gritstone Oncology to research, develop and commercialise cancer treatment products using cell therapy.

Gritstone Oncology will use its proprietary EDGE artificial intelligence platform to identify tumour-specific targets and natural T-cell receptors directed to those targets for use in bluebird bio's cell therapy platforms. bluebird bio will conduct all development, manufacturing and commercial activities. Gritstone Oncology will use its proprietary technology platform to allow patient selection for clinical development of such therapies.

According to the terms of the agreement, Gritstone Oncology will receive USD20m in an upfront payment and an additional USD10m in the form of a Series C preferred equity investment. In addition, Gritstone Oncology is eligible for development, regulatory and commercial milestones on any therapies, and tiered royalties on certain approved therapies.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 27, 2018
Words:164
Previous Article:Tradjenta trial realises primary endpoint.
Next Article:CVS Health opens new retail distribution centre in Missouri.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |